In the article questions of prevention of stroke, including repeated ones, are considered. The choice of anticoagulant therapy is discussed in patients with atrial fibrillation and a number of concomitant diseases - coronary artery disease, diabetes mellitus, chronic kidney disease, chronic heart failure. The data of subanalyses of a randomized clinical trial of ARISTOTLE are presented, indicating a high profile of efficacy and safety of the new oral anticoagulant apixaban in these categories of patients.
Research results show that poor glycemic control and recurrent episodes of severe hypoglycaemia are associated with a decrease in cognitive function in elderly people with type 2 diabetes mellitus (T2DM). On the other hand, patients with diabetes mellitus associated with cognitive impairment/dementia are most at risk of developing hypoglycaemic conditions. It is obvious that the relationship between hypoglycaemia and dementia is very complex and has a mutually aggravating nature.
Studies also show that individuals of older age groups with diabetes and cognitive impairment have a high risk of developing hypoglycaemic conditions, such as unwanted side effects from glucose-lowering therapy. In this case, of particular interest is the question that is being actively studied at the present time, which is concerning the effect of different groups of glucose-lowering antidiabetic drugs on the cognitive status and the rate of cognitive decline in diabetic patients with cognitive impairment.
In this review, we attempted to summarise, systematise, and present data available in the literature concerning the effect of hypoglycaemia on the risk of cognitive impairment and dementia in elderly and senile patients with type-2 diabetes, as well as the degree of participation in this process of of various groups of sugar-lowering antidiabetic drugs.
The climacteric period (menopause) is one of the most important periods in a woman's life, reflecting the natural extinction of the reproductive function. Current hormonal changes and developing menopausal disorders initiate the formation of pathological conditions that have a negative impact on both the health and expectancy of life and its quality. Cardiovascular diseases are one of the most common pathological conditions. Arterial hypertension (AH) is a key risk factor for the development of cardiovascular diseases, in different periods of menopause has various clinical and pathogenetic features that must be considered during treatment. Indapamide have pronounced antihypertensive effect, organprotective properties and metabolic neutrality. It is drug of choice for mono or combination therapy for women with hypertension during different periods of menopause. Effective antihypertensive and organprotective action, metabolic neutrality and safety of nitrendipine use allow us to recommend this drug for combination therapy of hypertension in women in distant menopause. The combination of indapamide and nitrendipine may be one of the most effective tools for hypertension treating in women in distant climacteric period.
Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of macrovascular complications in diabetes. In the context of influence on cardiovascular risks, modern glucose lowering drugs are considered, the safety and efficacy properties. Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk (obesity, hypertension).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.